Trial: 202009216

A Firstin-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

Phase

I

Principal Investigator

Morgensztern, Daniel

Disease Site

Lung; Lung Cancer – Small Cell

Learn more about this study at: clinicaltrials.gov